Press Release

<< Back

IRIDEX Introduces Modular Multi-Wavelength Laser Solution at the American Academy of Ophthalmology

MOUNTAIN VIEW, Calif., Oct. 21 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the introduction of a Modular Multi-Wavelength laser photocoagulator solution, which will be featured at the 2009 American Academy of Ophthalmology meeting in San Francisco.

"Our new Modular Multi-Wavelength solution allows us to compete in the multi-wavelength photocoagulator market segment with a flexible, reliable, and cost-effective solid-state system," commented Theodore A. Boutacoff, President & CEO. "Multi-wavelength laser systems are typically used in the office or clinic by ophthalmologists who specialize in treating the retina. Our offering uses two wavelengths: yellow (577) and infrared (810). Combining the preferred clinical capability of our high powered IQ 577 yellow laser with the flexibility of our IQ 810 and OcuLight SLx infrared lasers increases the physician's treatment options beyond a traditional multi-wavelength system while presenting a more economical solution. Traditional multi-wavelength laser systems include both a yellow and a green laser because the traditional yellow laser lacks sufficient power to perform all typical visible wavelength laser photocoagulation procedures. Our new offering is a full-featured, technically advanced, multi-wavelength solution with the added advantage of a modular design."

Both yellow and infrared laser modules can be purchased as separate standalone lasers and then, at any time, can be combined with an IRIDEX Symphony 2 Slit Lamp Adapter to create a multi-wavelength system tailored to meet the customer's specific needs.

IRIDEX also features MicroPulse technology for both 577 nm and 810 nm wavelength lasers. MicroPulse is a technology developed by IRIDEX that controls the accurate delivery of fine laser doses, which facilitates tissue-sparing laser treatments. No other multi-wavelength system can give both standard capabilities for photocoagulation along with the advanced technology for fine dose-control of laser therapy.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.

SOURCE IRIDEX Corporation

Jim Mackaness, Chief Financial Officer of IRIDEX Corporation, +1-650-940-4700